Delivering on the promise of Prime Editing. Terms: https://xitter.cf/t.co/vddichhAdf
Cambridge, MA
Joined April 2022
- Tweets178
- Following54
- Followers2.9K
- Likes1
We announced the first patient has been dosed in our global Phase 1/2 clinical trial of PM577a for H1069Q-mutated Wilson disease.
PM577 has also received FDA Rare Pediatric Disease designation.
Read more: tinyurl.com/mue7xe9e
#PrimeMedicine #WilsonDisease #GeneEditing
Thank you to @WilsonDiseaseA for an impactful Annual Conference. We valued connecting with patients, caregivers, advocates, healthcare professionals, and researchers to discuss Prime Editing and Prime-0201.
#WilsonDisease #RareDisease
The Prime team hit Blue Hills for a fall hike, led by our CMO, Mohammed Asmal, followed by a stop at Widowmaker Brewing. Great way to recharge together!
#TeamPrime #CompanyCulture
FDA has cleared the IND for PM647, our investigational in vivo Prime Editor for alpha-1 antitrypsin deficiency (AATD), designed to correct the most prevalent disease-causing mutation. Initial data expected in 2027. tinyurl.com/mum7reba
#PrimeEditing #AATD #GeneEditing
Join us at the @ASGCTherapy Policy Summit on Sept. 14, where Ann Lee, PhD, our CTO, will speak on a panel focused on expedited program flexibilities for CMC and advancing innovative therapies.
asgct.org/events-meetings/20…
#ASGCTPolicySummit #CellAndGeneTherapy #GeneEditing
Honored to be a nominee for the inaugural Prix Galien Patient First Award in Honor of Michael J. Fox.
This reflects our commitment to advancing transformative genetic medicines with patients at the core of what we do lnkd.in/d3hcpkNN
#PrixGalien #PatientFirst #PrimeEditing
We are excited to participate in 3 upcoming investor conferences:
Wells Fargo Healthcare (9/10)
H.C. Wainwright Global Investment (9/15)
Morgan Stanley Global Healthcare (9/16)
Webcasts available at: primemedicine.com
#PrimeEditing #Biotech #InvestorRelations
We're entering an exciting new phase.
PM577a cleared for clinical study in the U.S. & NZ.
PM647 advancing toward IND/CTA submission following favorable arbitration resolution
PM359 granted FDA RMAT designation
Read: tinyurl.com/PMQ2026
#PrimeEditing #GeneEditing #RareDisease
U.S. FDA cleared our IND for PM577a, our investigational in vivo Prime Editing therapy for H1069Q-mutated Wilson disease.
With our NZ CTA, this establishes a global Phase 1/2 program & positions us to advance PM577a.
More investors.primemedicine.com/…
#PrimeMedicine #Wilsondisease
Proud to contribute to Broad Institute-led PERC Gene Editing Platform, selected to receive up to $34.5M from @ARPA_H THRIVE program. Together we're working to advance gene-editing approaches for rare pediatric epilepsies, including Dravet syndrome & AHC. tinyurl.com/2tdfhf2v
We announced a positive resolution of our arbitration with Beam Therapeutics, confirming our right to develop and commercialize PM647, our investigational Prime Editing program for AATD, a disease with no approved disease-modifying or curative treatments.
Read more: investors.primemedicine.com/…
Proud to have sponsored the CGDAA Clinicians & Coffee session at the #IDF National Conference on June 26.
Great to support connection and collaboration in rare immune disease care.
#RareDisease #Immunology
Join us at #BIO2026 in San Diego!
Matthew Hawryluk, PhD, Prime Medicine’s CBO, will speak on:
Unlocking the Uncommon: Accelerating CGTs for Rare Diseases
Tuesday, June 23
1:45–2:45 PM
Room 32AB
#CellAndGeneTherapy #RareDisease #Biotech
Another important milestone: FDA has granted RMAT designation to PM359 for p47phox-deficient CGD — based on Phase 1/2 data published in NEJM. PM359 now holds RMAT + Fast Track + Orphan Drug + Rare Pediatric Disease Designations. #GeneEditing #RareDisease #FDA #PrimeEditing
Milestone moment:
✅ New Zealand Clinical Trial Application cleared for PM577a
✅ First clinical authorization for our in vivo Prime Editing therapy
✅ Phase 1/2 trial in Wilson disease to begin
A step toward a potential one-time genetic cure. Data expected 2027.
We’re excited to join the #Alpha1 National Conference, June 4–7 in San Diego! Our CMO, Mohammed Asmal, MD, PhD, will present in the Emerging Therapies in Alpha-1 session: Saturday, June 6th, 11:20 AM. Plus: Q&A with patients during the lunch session.
#RareDisease #GeneticMedicine
Prime Medicine management will join a fireside chat at the @GoldmanSachs 47th Annual Global Healthcare Conference on June 10, sharing updates on our strategy and progress advancing Prime Editing.
#PrimeMedicine #Biotech #GeneEditing
Read more: investors.primemedicine.com/…